|
Real-time Estimate
Cboe BZX
14:11:17 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 20.10 USD | +0.75% |
|
-1.51% | -24.30% |
| 09-28 | Neuren Says US Patent Allowance Could Extend Trofinetide Protection to 2041 | MT |
| 09-28 | Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent | MT |
Company Valuation: Acadia Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,752 | 2,578 | 5,140 | 3,053 | 4,519 | 3,437 | - | - |
| Change | - | -31.29% | 99.4% | -40.6% | 48% | -23.93% | - | - |
| Enterprise Value (EV) 1 | 3,231 | 2,161 | 4,702 | 2,297 | 3,699 | 2,429 | 2,200 | 1,706 |
| Change | - | -33.12% | 117.56% | -51.14% | 61.02% | -34.35% | -9.39% | -22.46% |
| P/E | -22.2x | -11.9x | -84.6x | 13.5x | 11.6x | 32.7x | 23.1x | 13.2x |
| PBR | 6.95x | 6.44x | 11.9x | 4.17x | 3.66x | 2.54x | 2.2x | 1.84x |
| PEG | - | -0.4x | 1.2x | -0x | 0.2x | -0.4x | 0.6x | 0.2x |
| Capitalization / Revenue | 7.75x | 4.98x | 7.08x | 3.19x | 4.22x | 2.7x | 2.4x | 2.14x |
| EV / Revenue | 6.67x | 4.18x | 6.47x | 2.4x | 3.45x | 1.91x | 1.54x | 1.06x |
| EV / EBITDA | -19.3x | -9.75x | -69.3x | 9.31x | 31.7x | 21.3x | 11.1x | 4.94x |
| EV / EBIT | -19x | -9.67x | -64.1x | 9.95x | 35.3x | 22.4x | 12.7x | 5.41x |
| EV / FCF | -25.5x | -19x | 282x | 14.6x | 35.2x | 10.4x | 22.8x | 5.31x |
| FCF Yield | -3.92% | -5.28% | 0.35% | 6.84% | 2.84% | 9.6% | 4.38% | 18.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.05 | -1.34 | -0.37 | 1.36 | 2.3 | 0.6106 | 0.8632 | 1.506 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 484.1 | 517.2 | 726.4 | 957.8 | 1,072 | 1,273 | 1,433 | 1,604 |
| EBITDA 1 | -167.1 | -221.6 | -67.83 | 246.7 | 116.6 | 114 | 198.2 | 345.2 |
| EBIT 1 | -170.4 | -223.6 | -73.38 | 230.8 | 104.8 | 108.4 | 173.2 | 315.2 |
| Net income 1 | -167.9 | -216 | -61.29 | 226.5 | 391 | 106.6 | 157.4 | 281.7 |
| Net Debt 1 | -520.7 | -416.8 | -438.9 | -756 | -819.7 | -1,009 | -1,237 | -1,731 |
| Reference price 2 | 23.34 | 15.92 | 31.31 | 18.35 | 26.71 | 19.95 | 19.95 | 19.95 |
| Nbr of stocks (in thousands) | 160,756 | 161,931 | 164,180 | 166,392 | 169,182 | 172,306 | - | - |
| Announcement Date | 2/28/22 | 2/27/23 | 2/27/24 | 2/26/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.67x | 1.91x | 21.31x | -.--% | 3.44B | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 22.14x | 28.42x | 13.36x | 0.28% | 39.4B | |
| Weighted average by Cap. | 22.36x | 31.77x | 13.62x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ACAD Stock
- Valuation Acadia Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
